Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development

Journal Article · · Journal of Medicinal Chemistry
DOI:https://doi.org/10.1021/jm401753e· OSTI ID:1497139
 [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1] more »;  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1] « less
  1. Departments of Therapeutic Discovery, ‡Pharmaceutics, and §Pharmacokinetics and Drug Metabolism, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, California, 94080, United States; Departments of Therapeutic Discovery, and ⊥Oncology Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States; Departments of Therapeutic Discovery, and ∇Pharmaceutics, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142, United States
+ Show Author Affiliations
Abstract not provided
Research Organization:
Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)
Sponsoring Organization:
INDUSTRY
OSTI ID:
1497139
Journal Information:
Journal of Medicinal Chemistry, Journal Name: Journal of Medicinal Chemistry Journal Issue: 4 Vol. 57; ISSN 0022-2623
Publisher:
American Chemical Society (ACS)
Country of Publication:
United States
Language:
ENGLISH

Similar Records

Optimization beyond AMG 232: Discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein–protein interaction
Journal Article · Fri Aug 01 00:00:00 EDT 2014 · Bioorganic and Medicinal Chemistry Letters · OSTI ID:1497142
Discovery of chiral dihydropyridopyrimidinones as potent, selective and orally bioavailable inhibitors of AKT
Journal Article · Fri Jun 01 00:00:00 EDT 2018 · Bioorganic and Medicinal Chemistry Letters · OSTI ID:1474162
Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent
Journal Article · Mon Jan 27 23:00:00 EST 2020 · ACS Medicinal Chemistry Letters · OSTI ID:1604185

Related Subjects